RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and
radiation treatment, reduces the incidence of severe oral mucositis in patients with head and
neck cancers. All patients in this study will receive 7 weeks of standard of care radiation
therapy given with the chemotherapy agent, cisplatin. Patients will receive RRx-001 or
placebo before start of standard of care treatment.